Gil Morgan MD

@weoncologists.bsky.social

Clinical Oncologist from Texas🇺🇸 @oncoalert.bsky.social Representative 🚨 Proudly NIH, NCI & MDA trained. An ounce of prevention equals a pound of cure. Views are own🌏

Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Jonathan Zager 🇺🇸 Moffit Cancer Center Presenting on Melanoma Staging and Molecular Testing Presentation reviews current AJCC staging system for melanoma, outline present state of staging practices, and explore potential areas for refinement

BildBildBildBild

Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Anders Thornell 🇸🇪 Sahlgrenska Mock Debate: Should follow-up for operated GIST tumors be escalated or de-escalated? Two experts go head-to-head over early relapse detection, second cancer risk, scan burden, and guideline evolution.

BildBildBild

Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Laura Lorenzon 🇮🇹 Investigation and Management of GI Symptoms After Surgery This presentation highlights the main dimensions related to quality of life, the main metrics used to measure symptoms and the main issues in this field

BildBildBildBild

Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Wim Ceelen 🇧🇪 Ghent Physically Enhanced IP Drug Delivery Tumor tissue penetration is very limited after intraperitoneal drug delivery, hampering its clinical efficacy. I discuss how physical methods overcome transport barriers.

BildBildBildBild

Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Elinor Bexe Lindskog 🇸🇪 The Immune Microenvironment in Peritoneal Metastases The immune landscape of peritoneal metastases differs from other metastatic sites. Peritoneal lesions show a fibro-inflammatory, immune-regulated niche

BildBildBildBild

See you in Berlin for #ESMO25! The OncoAlert AF is ready to bring you all the great science coming out of Germany🇩🇪 . We encourage you to follow these outstanding colleagues, and—as always—OncoAlert will be on the ground reporting in real time on all the latest news and trials.

Day2⃣of #IUCS25 🇬🇧Portsmouth Dr. Enrique Grande 🇪🇸 discusses “Geting more patient the right 1st line in Bladder Cancer.” 👉 improving patient selection, refining dosing strategies, and developing predictive tools are key to making sure more patients receive and benefit the right first-line tx

BildBildBildBild

Day2⃣of #IUCS25 🇬🇧Portsmouth Dr. Petros Grivas🇺🇸 discusses “How Perioperative Treatment is Evolving in Bladder Cancer.” 📌 The perioperative space in MIBC is rapidly transforming—biomarkers, immunotherapy, ADCs, and combinations are reshaping the standard of care.

BildBildBildBild